CN 128

Drug Profile

CN 128

Alternative Names: CN128

Latest Information Update: 02 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hangzhou Zede Pharmaceutical Technology
  • Class Antianaemics; Heterocyclic acids; Pyridones; Small molecules; Thiazoles
  • Mechanism of Action Iron chelating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Thalassaemia
  • Preclinical Iron overload

Most Recent Events

  • 01 Jan 2018 Phase-I clinical trials in Thalassaemia in China (PO) (ChiCTR-OIC-17014216)
  • 08 Nov 2016 Hangzhou Zede Pharmaceutical Technology plans a phase I trial of CN 128 in healthy volunteers in Thailand (TCTR20161110001)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top